1. Expression and Prognostic Value of a Novel B7-H3 (CD276) Antibody in Acute Myeloid Leukemia.
- Author
-
Stefańczyk, Sylwia A., Hayn, Clara, Heitmann, Jonas, Jung, Susanne, Zekri, Latifa, and Märklin, Melanie
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *FLOW cytometry , *RISK assessment , *RECEIVER operating characteristic curves , *T-test (Statistics) , *RESEARCH funding , *KRUSKAL-Wallis Test , *FISHER exact test , *TUMOR markers , *DESCRIPTIVE statistics , *MANN Whitney U Test , *CHI-squared test , *MICE , *ANIMAL experimentation , *PROGRESSION-free survival , *COMPARATIVE studies , *OVERALL survival - Abstract
Simple Summary: We evaluated a novel proprietary murine B7-H3 antibody 8H8 for flow cytometric analyses of patients with acute myeloid leukemia (AML). The results showed substantial B7-H3 expression in a significant proportion of AML cases, particularly in the M5 group and in those with intermediate or poor risk profiles. The correlation between high B7-H3 expression and poorer overall and progression-free survival suggests that B7-H3 may serve as an additional promising negative prognostic marker to be considered in treatment decisions in AML. Despite recent advances in immunophenotyping, the prognosis of acute myeloid leukemia (AML) is still mainly estimated using age and genetic markers. As the genetic heterogeneity of AML patients is high, flow cytometry-based classification with appropriate biomarkers can efficiently complement risk stratification and treatment selection. An increased expression of B7-H3 (CD276), an immune checkpoint protein, has been reported and associated with poor prognosis. However, the available data are limited and heterogeneous. Here, we used a novel, proprietary murine anti-B7-H3 8H8 antibody for the flow cytometric analysis of B7-H3 expression in AML blasts from 77 patients. Our antibody reliably detected substantial B7-H3 expression in 62.3% of AML patients. B7-H3 expression was higher in the monocytic French–American–British (FAB) M5 group and in intermediate and poor risk patients according to the European Leukemia Network. Using receiver operating characteristics (ROCs), we identified a specific fluorescence intensity cut-off of 4.45 to discriminate between B7-H3high and B7-H3low expression. High B7-H3 expression was associated with shorter overall survival (OS) and progression-free survival (PFS). In conclusion, we have developed a novel B7-H3 antibody that serves as a new tool for the detection of B7-H3 expression in AML and may help to facilitate risk stratification and treatment selection in AML patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF